Evotec SE upgraded by Morgan Stanley with a new price target
$EVO
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley upgraded Evotec SE from Equal-Weight to Overweight and set a new price target of $16.00 from $12.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2024 | Buy → Hold | Jefferies | |
| 8/8/2024 | Hold → Sell | Deutsche Bank | |
| 7/29/2024 | $15.00 → $6.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/11/2024 | Buy → Hold | Deutsche Bank | |
| 4/12/2024 | Hold → Buy | Deutsche Bank | |
| 1/18/2024 | Sector Perform → Outperform | RBC Capital Mkts | |
| 6/23/2023 | $12.00 → $16.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/16/2023 | $13.00 | Buy → Neutral | BofA Securities |
6-K - Evotec SE (0001412558) (Filer)
6-K - Evotec SE (0001412558) (Filer)
20-F - Evotec SE (0001412558) (Filer)
SC 13D - Evotec SE (0001412558) (Subject)
SC 13G/A - Evotec SE (0001412558) (Subject)
SC 13G/A - Evotec SE (0001412558) (Subject)
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm
Most agenda items adopted with great majorityAnnual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario PolywkaHAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO) today announced that its shareholders approved most of the proposals the Company's Management put to vote at the Company's Annual General Meeting 2024 with great majority.Under the topic "Together for Medicines that Matter - Weg zum Neustart", the Chairperson of the Supervisory Board of Evotec SE, Prof. Dr Iris Löw-Friedrich, Chief Business Officer Dr Matthias Evers and Chief Fina
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire from his position at the end of June and will also not seek re-election for his dormant Supervisory Board mandate, which expires with the 2024 Annual General Meeting.Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of
Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies Would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond All-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close SAN DIEGO, Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ:EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ: EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.Contact: Volker Braun, EVP Head of Global
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ:EVO) ("Evotec") to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. The proposal represents a premium of 109% to Evotec's undisturbed share price on October 15, 2024, the day prior to Triton Partners' initial accumulation of Evotec shares, and a premium of 7
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday. Shares of Delta Air Lines, Inc. (NYSE:DAL) fell sharply in today's pre-market trading after the company posted downbeat second-quarter earnings and issued lower-than-expected third-quarter earnings outlook. Delta Air Lines reported quarterly earnings of $2.36 per share which missed the analyst consensus estimate of $2.37 per share. The company reported quarterly sales of $16.658 billion which beat the analyst consensus estimate of $15.452 billion, according to data from Benzinga Pro. Delta Air Lines shares fell 9% to $42.65 in the pre-market trading session. Here are some big stoc
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases The research will be carried out at Evotec's sites in France, including Campus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evotec will receive research support funding from Pfizer and be eligible for potential milestones and royalties related to success of the programs.
German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concerns about the company’s vulnerability to a takeover. Multiple buyout firms are reportedly evaluating Hamburg-based Evotec as a potential acquisition target, initiating early discussions with advisers to assess the company’s drug pipeline and strategic value. Evotec’s shares surged. The spike follows a year-to-date decline of over 60%, with the stock recently hitting its lowest since March 2017. The drop came after Intron Health analysts downgraded the stock from “buy” to “sell.” Bloomberg noted, citing sources, that despite the market activ
Jefferies downgraded Evotec SE from Buy to Hold
Deutsche Bank downgraded Evotec SE from Hold to Sell
Morgan Stanley downgraded Evotec SE from Overweight to Equal-Weight and set a new price target of $6.00 from $15.00 previously
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutionsPriority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) today announced its financial results and corporate upda
HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English.Webcast detailsDate: Wednesday, 06 November 2024Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our we
Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been acceleratedChallenging market environment and high fixed cost base led to weaker profitability. Priority reset towards profitable growth gaining momentumDr Christian Wojczewski, CEO as of 1 July, is announcing an accelerated transformation programme for the company, building on the core innovation strengths of Evotec HAMBURG, G